Dyskerin expression influences the level of ribosomal RNA pseudo-uridylation and telomerase RNA component in human breast cancer

Journal of Pathology

Volumn 210, Issue 1, 2006, Pages 10-18

  Montanaro, Lorenzo ^a,c   Brigotti, M ^a   Clohessy, J ^b   Barbieri, S ^a   Ceccarelli, C ^a   Santini, D ^a   Taffurelli, M ^a   Calienni, M ^a   Teruya Feldstien, J ^b   Trere D ^a   Pandolfi, P P ^b   Derenzini, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Memorial Sloan Kettering Cancer Center ^*  (Italy)

Author keywords

Cancer; Dyskerin; rRNA processing; Telomerase

Indexed keywords

DYSKERIN; MESSENGER RNA; RIBOSOME RNA; RNA; TELOMERASE;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME ACTIVITY; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEOLUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE;

BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHOMA, B-CELL; NEOPLASM PROTEINS; NUCLEAR PROTEINS; RNA, MESSENGER; RNA, NEOPLASM; RNA, RIBOSOMAL; TELOMERASE;

EID: 33747876210     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2023     Document Type: Article

References (29)

1. Heiss NS, Knight SW, Vulliamy TJ, Klauck SM, Wiemann S, Mason PJ, et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nature Genet 1998;19:32-38.
2. Wang C, Query CC, Meyer UT. Immunopurified small nucleolar ribonucleoprotein particles pseudouridylate rRNA independently of their association with phosphorylated Nopp140. Mol Cell Biol 2002;22:8457-8466.
3. Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 1999;402:551-555.
4. Ruggero D, Grisendi S, Piazza F, Rego E, Mari F, Rao PH, et al. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 2003;299:259-262.
5. Mochizuki Y, He J, Kulkarni S, Bessler M, Mason PJ. Mouse dyskerin mutations affect accumulation of telomerase RNA and small nucleolar RNA, telomerase activity, and ribosomal RNA processing. Proc Natl Acad Sci USA 2004;101:10756-10761.
6. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol 2000;110:768-779.
7. Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997;91:25-34.
8. He J, Navarrete S, Jasinski M, eVulliamy T, Dokal I, Bessler M, et al. Targeted disruption of Dkcl, the gene mutated in X-linked dyskeratosis congenita, causes embryonic lethality in mice. Oncogene 2002;21:7740-7744.
9. Hedvat CV, Hegde A, Chaganti RS, Chen B, Qin J, Filippa DA, et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol 2002;33:968-974.
10. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
11. Faccioli S, Chieco P, Gramantieri L, Stecca B, Bolondi L. Cytometric measurement of cell proliferation in echo-guided biopsies from focal lesions of the liver. Mod Pathol 1996;9:120-125.
12. Derenzini M, Trere D, Pession A, Montanaro, L, Sirri V, Ochs RL. Am J Pathol 1998;152:1291-1297.
13. Yajima T, Yagihashi A, Kameshima H, Kobayashi D, Furuya D, Hirata K, et al. Quantitative reverse transcription-PCR assay of the RNA component of human telomerase using the TaqMan fluorogenic detection system. Clin Chem 1998;44:2441-2445.
14. Kuo KC, Smith CE, Zhixian S, Agris PF, Gehrke CW. High performance liquid chromatography of cap structures and nucleoside composition of mRNAs. In Chromatography and Modification of Nucleosides, Gehrke CW, Kuo KC (eds). Elsevier: Amsterdam, 1990; 297-316.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
16. Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:87-220.
17. Hisatomi H, Nagao K, Kanamaru T, Endo H, Tomimatsu M, Hikiji K. Levels of telomerase catalytic subunit mRNA as a predictor of potential malignancy. Int J Oncol 1999;14:727-732.
18. Zhu Y, Tomlinson RL, Lukowiak AA, Terns RM, Terns MP. Telomerase RNA accumulates in Cajal bodies in human cancer cells. Mol Biol Cell 2004;15:81-90.
19. Derenzini M. The AgNORs Micron 2000;31:117-120.
20. Treré D, Borzio M, Morabito A, Borzio F, Roncalli M, Derenzini M. Nucleolar hypertrophy correlates with hepatocellular carcinoma development in liver cirrhosis due to HBV infection. Hepatology 2003;37:72-78.
21. Reddel R. Alternative lengthening of telomeres, telomerase, and cancer. Cancer Lett 2003;194:155-162.
22. Atkinson SP, Hoare SF, Glasspool RM, Keith WN. Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res 2005;65:7585-7590.
23. Naito Y, Takagi T, Handa O, Ishikawa T, Matsumoto N, Yoshida N, et al. Telomerase activity and expression of telomerase RNA component and catalytic subunits in precancerous and cancerous colorectal lesions. Tumour Biol 2001;22:374-382.
24. Giordano E, Peluso I, Senger S, Furia M. Minifly, a Drosophila gene required for ribosome biogenesis. J Cell Biol 1999;144:1123-1133.
25. Ruggero D, Pandolfi PP. Does ribosome translate cancer? Nature Rev Cancer 2003;3:179-192.
26. Poole JC, Andrews LG, Tollefsbol TO. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene 2001;269:1-12.
27. Saretzki G. Telomerase inhibition as cancer therapy. Cancer Lett 2003;194:209-219.
28. Poremba C, Heine B, Diallo R, Heinecke A, Wai D, Schaefer KL, et al. Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol 2002;198:181-189.
29. Kimura M, Koida T, Yanagita Y. A study on telomerase activity and prognosis in breast cancer. Med Oncol 2003;20:117-126.